中
  • Home
  • About Us

    • Company Overview
    • R&D Leader
    • R&D Team
    • Board of Directors
    • Partners
  • R&D

    • R&D Strategy
    • Medical Information
  • Pipeline

    • TGRX-678 BCR-ABL inhibitor
    • TGRX-326 ALK/ROS1 inhibitor
    • TGRX-814 BCL2 inhibitor
  • News

  • Partnering

  • Careers

    • Opportunities
    • Company Culture
  • Contact

    • Contact Us
    • Message

News

Mission drives innovation, and innovation improves quality of life

News

  • AACR 2025 | Preclinical Results of TGRX-3911 Unveiled, Potentially Addressing Clinical Resistance Challenges of Current BTK Inhibitors2025-04-30 Views:26

    TargetRx presented preclinical data of its oral BTK degrader TGRX-3911 at the 2025 American As ...

  • AACR 2025 | Preclinical Data Disclosure of TGRX-3544: An Oral, Highly Mutant-selective KIT Degrader2025-04-30 Views:32

    At the 2025 AACR Annual Meeting, TargetRx presented preclinical results for TGRX-3544 for the first time i ...

  • AACR 2025 | TargetRx Reveals First Preclinical Data on Two Novel, Oral Potent Protein Degraders2025-03-28 Views:115

    Two novel targeted protein degraders (TPD) developed by TargetRx - TGRX-3544, an orally active and highly mutation ...

  • TargetRx Completes Series C Financing2025-01-22 Views:800

    Shenzhen TargetRx, Inc announced today that it has successfully completed its Series C financing, raising $50 mil ...

  • 2024 ASH Poster | Preclinical Results of TGRX-678 on Its Potential Blood-Brain Barrier Penetration Ability2024-12-16 Views:125

    At the 66th Annual Meeting of the American Society of Hematology (ASH) in 2024, Shenzhen Ta ...

  • 2024 ASH Poster | TargetRx Presents Preclinical Results of TGRX-3247, a Highly Potent, Broad-Spectrum Oral BCR::ABL1 Degrader2024-12-16 Views:154

    TargetRx presented the preclinical research results of TGRX-3247 for the first time at the 6 ...

41 Items Prev 1 2 3 4 5 6 7 Next

About Us

R&D

Pipeline

News

Partnering

Careers

Contact

  • Tel: +86-0755-86934300
  • 3rd Floor, Building A1, Kexing Science Park, No. 15 Keyuan Rd., Nanshan District, Shenzhen, China
  • E-mail: targetrx@tjrbiosciences.com

Follow Us

  • Tel: +86-0755-86934300
  • 3rd Floor, Building A1, Kexing Science Park, No. 15 Keyuan Rd., Nanshan District, Shenzhen, China
  • E-mail: targetrx@tjrbiosciences.com
Copyright © 2021 Shenzhen TargetRx, Inc.
粤ICP备2021119553号